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Objective: Concern about the durability of small homograft cardiac valves
has been expressed by surgeons, and evidence has been found that
homograft valves evoke a recipient immune response. We reviewed our
experience with homograft valves for evidence of rejection. Methods: A
search of our files revealed 11 homograft cardiac valves removed at
reoperation and one at autopsy. Six valves were from adults, five were from
infants, and one was from a 13-year-old child. Immunohistochemical
studies with antibodies against smooth muscle actin, CD20, CD43, CD34,
and CD68 were performed on the homografts containing inflammatory
infiltrates. These valves happened to be the valves from the five infants.
These five valves were also stained with Gram and Gomori’s methenamine
silver stains. Results: The failed homografts from the adults and 13-year-old
child showed leaflet calcification, fibrosis, and degeneration, but no inflam-
mation. The valves from the infants all failed in less than 8 months. The
valve leaflets were thickened, and the valve leaflets and aortic sleeves
contained a hyperplastic intimal layer with numerous spindle cells positive
for smooth muscle actin embedded in a glycosaminoglycan matrix. The
homografts contained multiple foci of inflammation consisting of T lym-
phocytes (in all five infant valves) and B lymphocytes (in three of the five
infant valves). Special stains for organisms were negative. Conclusions:
Rapid failure plus lymphocytic infiltration in valve leaflets and aortic
sleeves is consistent with rejection. The hyperplastic intima is similar to
coronary arteries in transplant-associated vascular disease. Our observa-
tions are consistent with other reports of rapid failure of homograft valves
in this age group. (J Thorac Cardiovasc Surg 1998;115:111-7)
Aortic valve replacement with homograft valveswas introduced in 1962.1 Since then, homografts
(allografts) have been used to treat both acquired
and congenital heart diseases. The main advantages
over mechanical valves are the good hemodynamic
performance and a relative freedom from valvular
thrombosis in the absence of anticoagulation ther-
apy. Although much has been written on the long-
term durability of aortic valve homografts,2-8 con-
cerns have been expressed about the durability of
homograft valves in younger pediatric patients.9, 10
Homograft valves are usually transplanted without
matching donor and recipient for blood group or
human leukocyte antigens (HLA). Theoretically, the
lack of blood vessels in cardiac valves should protect
them from rejection. However, homografts can induce
specific immune responses in vivo and in vitro in both
animals and human beings,11-18 and it seems likely that
the early homograft failure in young children is asso-
ciated with immunologic factors. This observation has
led to suggestions that short-course immunosuppres-
sion therapy might improve the durability of ho-
mograft valves, even though the cause of the rapid
failure of homografts in some children has not yet
been determined. We reviewed our experience with
homograft valves at The Cleveland Clinic Foundation
for evidence of possible rejection.
Materials and methods
The files at The Cleveland Clinic Foundation were
searched for all homografts that had been removed at
operation or reported at autopsy. Multiple sections (rang-
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ing from 3 to 25, median 7) were taken from the explanted
homograft valves and the homograft valve removed at
autopsy. The tissue sections were fixed in 10% buffered
formalin solution and embedded in paraffin. Sections 4
mm in size were obtained and stained with hematoxylin
and eosin. After the sections stained with hematoxylin and
eosin had been reviewed, further immunohistochemical
studies were performed on all homografts containing an
inflammatory infiltrate. With the use of an immunoperox-
idase method, immunohistochemical evaluations with an-
tibodies against smooth muscle actin, CD20 (for B lym-
phocytes), CD43 (for T lymphocytes), CD34, and CD68
(macrophages) were performed.19 In addition Gram, Go-
mori’s methenamine silver, and Movat’s pentachrome
special stains were also used on these homografts with an
inflammatory infiltrate to exclude infectious causes of
inflammation and to clarify valve and aortic sleeve struc-
ture. When the gross, microscopic, and immunohisto-
chemical findings in these cases were recorded, both the
valve leaflets and the aortic sleeve were considered to be
part of the graft because the aortic sleeves had been
transplanted with the valve leaflet as part of the aortic
homograft.
Results
Our search revealed 11 aortic homograft cardiac
valves removed at reoperation and one at autopsy.
Eleven of the valves were removed from the aortic
position and one was from the pulmonary position.
Six of the valves came from adults (ages ranging
from 19 to 37 years at the time of valve insertion),
one from a child of 13 years, and five from four
infants (less than 1 year old at the time of valve
insertion and explantation). One child had two
aortic homografts removed at reoperation on sepa-
rate occasions.
The 13-year-old child had the homograft valve
inserted at an outside hospital when she was 6 years
of age. It was replaced 7 years later for aortic
insufficiency. Of the six adults, only one patient had
the homograft inserted at The Cleveland Clinic.
Available records for this patient reveal that the size
of this homograft was 21 mm but the method of
valve preservation and the sex and blood type of the
valve donor are unknown. Similar information is
also unavailable for the remaining five adults (as
their homograft valves were inserted at various
outside hospitals), except for one man whose ho-
mograft valve was known to have been cryopre-
served. The length of graft survival for this patient
was 6 years. The adult patients were all male, and
lengths of graft survival ranged from 1.2 years to 23
years (median 6 years). The homografts were ex-
planted because of aortic insufficiency in five of the
six adults and suspected bacterial endocarditis in the
other adult (no histologic evidence of suppurative
inflammation).
Homografts from the 13-year-old child and the six
adults showed similar histologic findings character-
ized by fibrosis, degeneration of leaflet collagen,
calcification, and leaflet tears. Inflammation was not
present. These changes are similar to those found in
failed xenograft valves.
The five infant homograft valves were all im-
planted at The Cleveland Clinic Foundation and all
five valves were cryopreserved. Information regard-
ing valve sizes, sex and blood type of recipients and
donors (the blood type of only two of the donors was
known), age of infants at the time of valve insertion,
length of graft survival, and available clinical infor-
mation on indications for graft replacement is re-
corded in Table I.
The five homograft valves from the four infants
contained a cellular infiltrate. Each of these valves
had failed in less than 8 months and evidence of
valve failure was noted 3 weeks after implantation at
the earliest (patient 4) and 9 weeks at the latest
(patients 2, 3, and 5). Four of the five valves were
insufficient and the sleeve of the fifth homograft had
become aneurysmal. Gross inspection of each ex-
planted infant homograft valve revealed thickened
valve leaflets. In the valve from the autopsy case,
visualization of the homograft valve in situ revealed
retracted valve leaflets that failed to coapt (Fig. 1).
Microscopic examination of the valve leaflets and
Fig. 1. Aortic valve in situ, from infant autopsy case,
demonstrating thickening and retraction with failure of
the valve leaflets to coapt.
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aortic sleeves revealed a markedly thickened cellu-
lar intimal layer with numerous spindle cells embed-
ded in a glycosaminoglycan matrix in all valves from
the infants. These spindle cells were positive for
smooth muscle actin (Fig. 2). Elastic tissue could be
identified in the leaflets, but the normal layers of the
valve beneath the hyperplastic intima were obscured
by collagen. All five homografts from the infants
contained multiple foci of inflammation, composed
primarily of lymphocytes, in the valve leaflets (Fig.
3) and intima, media, and adventitia of the aortic
sleeves (Fig. 4). The lymphocytes were present in
aggregates of varying sizes in the aortic sleeves and
as scattered individual cells in the valve leaflets. T
lymphocytes, identified by a positive staining reac-
tion with CD43 (Fig. 5), were predominant in all five
homografts, and B lymphocytes, identified by a
positive staining reaction with CD20 (Fig. 6), were
present in three of the five homografts. Macro-
phages were identified in only one valve. A few
Fig. 2. Aortic sleeve from infant aortic homograft highlighting the spindle cell proliferation in the intima
and the mononuclear inflammatory cell infiltrate present between the intima and media. (Hematoxylin and
eosin; original magnification 3190.) Inset: The spindle cells of the intima were identified as smooth muscle
cells by demonstrating a positive staining pattern with antibodies against smooth muscle actin.
Table I. Clinical data on homografts from infants
Patient
Valve
replaced
Valve size
(mm)
Sex Blood type
Age at
insertion
Time of onset
of symptoms from
insertion (wk)
Indications for
graft replacement
Length of
graft survival (wk)R D R D
1 AV 9 F M A1 U 21⁄2 wk 4 Severe AI presenting with
acute respiratory distress*
61⁄2
2 AV 11 M M O1 O2 4 wk 9 Progressive AI leading to
severe cardiac failure
15
3† AV 9 M M O1 U 6 days 9 Significant AI 18
4† AV 11 M M O1 U 18 wk 3 Progressive AI 31
5 PV 9 F M A1 O1 1 day 9 Developed aneurysm
of homograft
13
AV, Aortic valve; PV, pulmonary valve; R, recipient; D, donor; F, female; M, male; U, unknown; AI, aortic insufficiency.
*Patient died as a result of severe aortic insufficiency.
†Indicates the same patient.
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Fig. 4. An example of one of the multifocal mononuclear inflammatory cell infiltrates present in the aortic
sleeve of an infant aortic homograft. (Hematoxylin and eosin; original magnification 3310.)
Fig. 3. Homograft valve leaflet highlighting the spindle cell proliferation on the surface of the valve and
the mononuclear inflammatory cells infiltrating the valve leaflet. (Hematoxylin and eosin; original
magnification 3230).
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Fig. 5. Immunohistochemical stain for CD43 demonstrating a positive staining pattern in the lymphocytes
infiltrating an infant homograft cardiac valve. (Original magnification 3320.)
Fig. 6. Lymphocytic infiltrate in infant homograft valve demonstrating a positive staining pattern with
CD20. (Original magnification 3650.)
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eosinophils were found as part of the mononuclear cell
infiltrate in one valve. Organizing mural thrombi were
present in the homograft from the autopsy case. The
Gomori methenamine silver and Gram stains for
organisms were negative in all homograft valves. Other
than the lymphocytic infiltrate, the media of the aortic
sleeves, including the elastic lamellae, appeared unal-
tered. The adventitia of the aortic sleeves in the infant
homograft valves was fibrotic, but no more so than
would be expected in any postoperative state.
Discussion
In transplanted solid organs, including the heart,
an infiltrate of T lymphocytes, coupled with altered
structure and function, has been accepted as evi-
dence of rejection. Rapid failure of the aortic ho-
mograft valve in these four infants, with a predom-
inately T-cell lymphocytic infiltrate in the valve
leaflets and aortic sleeves, is therefore consistent
with rejection. That interpretation is buttressed by a
recent report that donor-specific T lymphocytes can
be cultured from explanted homografts.18 Treat-
ment with cyclosporine (INN: ciclosporin) has been
shown to arrest homograft degeneration in rat mod-
els, thus suggesting that such degeneration is caused
by rejection.20 The hyperplastic intima (in all five
valves) and thrombus formation (in the autopsy
case) are similar to the findings seen in coronary
arteries in transplant-associated vascular disease
(accelerated atherosclerosis).21 Four of the five
valves in the children failed as a result of insuffi-
ciency. The hyperplastic intima, as well as fibrosis of
the leaflets and the sleeves, seems to have resulted
in retraction of the leaflets. Why we found ho-
mograft valve rejection only in infants is not clear,
but our findings are consistent with other reports of
rapid failure of homografts in young children.9, 10
Other investigators have also observed aggregates of
lymphocytes in homograft valves that were removed
after a brief period of implantation, but they did not
note the specific ages of the patients or the reasons
for valve removal in these specific cases.22 Some
authors suggest that homograft size may be a possi-
ble explanation for homograft failure in young re-
cipients.9 Smaller homografts would be less suscep-
tible to internal manipulation during dissection,
which in turn would lead to less endothelial denud-
ing than would take place in larger homografts.
Graft endothelial cell membranes are positive for
human leukocyte antigen (HLA) classes I and II,
and maintaining cell viability, especially of endothe-
lial cells, may promote rejection.
Another important factor in homograft valve re-
jection may be related to the method of pretrans-
plantation preservation of those valves. Cryopreser-
vation maintains cellular and tissue viability,14 which
is thought to be key to the durability of cryopre-
served homograft valves.23 However, maintaining
cellular viability (especially endothelial cell viability)
may result in an increased antigenic stimulus, as
discussed earlier. All five homografts implanted in
infants in our study had been cryopreserved, but the
method of valve preservation is unknown for most of
the adult homografts. Therefore it is difficult to
make a comparison between the two groups with
regard to method of preservation and time to valve
failure.
Finally, as previously mentioned, cardiac valve
homografts are usually transplanted without match-
ing donor and recipient for blood group or HLA.
This is in contrast to the protocol used for patients
undergoing heart transplantation who, in addition,
receive triple immunosuppression therapy. One
study of 37 patients who died, on average (mean),
398 days after heart or heart-lung transplantation
focused on the aortic valve.24 Optimal cusp viability
and integrity were observed, even at long term, in
these patients, suggesting that blood group or HLA
matching and chronic immunosuppression may pre-
vent early degeneration of the homograft valve.
The question of whether ABO compatibility affects
the immunologic response has been debated on many
occasions. No attempts to match the blood group of
the recipient and donor were made for the five infant
homograft valves in our study. In fact, the blood type
of three of the five donors was never recorded.
In summary, in our series, all failed cardiac ho-
mograft valves in infants less than 1 year of age
showed evidence of cellular rejection. All valves that
demonstrated rejection had been cryopreserved.
Cryopreserved homograft valves may not be immu-
noprivileged, and therefore consideration of mea-
sures to control rejection, such as blood group and
HLA matching as well as immunosuppression, may
be warranted.
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